Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

Yahoo Finance • 2 days ago

Veeva's Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings, Truist Says

Veeva Systems' (VEEV) Vault CRM has cemented its position as the clear market leader in life science PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 days ago

Veeva Vault CRM Selected by Regeneron

Leading biopharma company selects agentic CRM for life sciences to generate Commercial Evidence PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Regeneron Pharmaceuticals has committed to V... Full story

Yahoo Finance • 7 days ago

Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy

In August 2026, Regeneron Pharmaceuticals announced that the US FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva, based on positive Pha... Full story

Yahoo Finance • 8 days ago

Regeneron wins FDA nod for rare bone disorder therapy

[FDA Headquarters] * The U.S. Food and Drug Administration on Wednesday approved Pasatru, a treatment developed by Regeneron (REGN [https://seekingalpha.com/symbol/REGN]) for adults with an ultra-rare bone growth disorder known as fibro... Full story

Yahoo Finance • 8 days ago

Billionaire Ken Griffin Increased His Position in This Dividend King by 547%

Billionaire hedge fund manager Ken Griffin was in the news after he scooped up most of the public stock portfolio formerly held by Situational Awareness late last month. In what was otherwise a bad month for hedge funds, Griffin's Citadel... Full story

Yahoo Finance • 10 days ago

Ocular gains on EyePoint phase 3 wet AMD miss

[AMD Abbreviation or acronym of age-related macular degeneration - eye problem in older persons. Word AMD is on foreground near eye model with stethoscope and visual acuity test on blurry background] Shidlovski * Ocular Therapeutix (OCU... Full story

Yahoo Finance • 18 days ago

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Aug. 09, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)... Full story

Yahoo Finance • 19 days ago

Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Dividend, earnings and buybacks in focus Regeneron Pharmaceuticals (REGN) has given investors several fresh data poin... Full story

Yahoo Finance • 22 days ago

Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit – Hagens Berman

SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerni... Full story

Yahoo Finance • 23 days ago

REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class Action - Contact SueWallSt

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- SueWallSt alerts investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action has been filed on behalf of shareholders who purchased securities between August 1, 2... Full story

Yahoo Finance • 24 days ago

REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure

SAN FRANCISCO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patient... Full story

Yahoo Finance • 27 days ago

Biotech Stocks Facing FDA Decision In August 2026

(RTTNews) - As we head into August, it's time for our monthly roundup of the upcoming FDA decisions that could move biotech stocks. The August regulatory calendar spans a wide range of indications - from the ultra-rare Fibrodysplasia Ossi... Full story

Yahoo Finance • 27 days ago

Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation

Early-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharma... Full story

Yahoo Finance • 28 days ago

Regeneron expects EYLEA HD demand growth in the low to mid-teens in Q3–Q4 2026 amid prefilled syringe push

Earnings Call Insights: Regeneron Pharmaceuticals (REGN) Q2 2026 MANAGEMENT VIEW * “Regeneron delivered another strong quarter with total revenues up 17% and non-GAAP earnings per share up 11% compared to the second quarter of 2025,” a... Full story

Yahoo Finance • 28 days ago

Regeneron beats quarterly estimates on eczema drug strength, shares rise

July 30 (Reuters) - Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped ‌by strong demand for its eczema drug Dupixent ‌and a high-dose version of its eye drug Eylea. Shares rose nearly ​5% befor... Full story

Yahoo Finance • 28 days ago

Regeneron Reports Second Quarter 2026 Financial and Operating Results

Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025Dupixent® global net sales(recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion EYLEA HD® U.S. net sales increased 52% to a new all-ti... Full story

Yahoo Finance • 29 days ago

REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) of the September 14, 2026 deadline... Full story

Yahoo Finance • 29 days ago

3 Biotech Stocks With Massive Upside to Buy Before August Starts

Quick Read REGN sits 15% below its year-start price despite strong earnings, while MRNA has surged 177% into an August 5 FDA flu vaccine ruling. VKTX carries 175% analyst upside potential but remains pre-revenue, making its dual GLP-1/GIP... Full story

Yahoo Finance • 30 days ago

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- SueWallSt notifies investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a class action has been filed on behalf of shareholders who purchased securities between August 1, 2025 and M... Full story

Yahoo Finance • last month

REGN DEADLINE: Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline

NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action has been filed on behalf of shareholders who purchased Regeneron securi... Full story